Profil
Kevin Friedman is the founder of Kelonia Therapeutics, Inc. He currently holds the titles of President, Chief Executive Officer, and Director at the company.
Aktive Positionen von Kevin Friedman
| Unternehmen | Position | Beginn |
|---|---|---|
Kelonia Therapeutics, Inc.
 Kelonia Therapeutics, Inc. BiotechnologyHealth Technology Kelonia Therapeutics, Inc. is a company based in Cambridge, MA that is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS™). The company's simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia Therapeutics is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. The company was founded by Michael Fischbach, Michael Birnbaum. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Kelonia Therapeutics, Inc.
Kelonia Therapeutics, Inc. BiotechnologyHealth Technology Kelonia Therapeutics, Inc. is a company based in Cambridge, MA that is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS™). The company's simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. Initially focused on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia Therapeutics is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. The company was founded by Michael Fischbach, Michael Birnbaum. | Health Technology |
